Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to $25.5 million.

  • Black Diamond Therapeutics' Cash from Financing Activities fell 76.30% to $64,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.6 million, marking a year-over-year decrease of 99.54%. This contributed to the annual value of $25.5 million for FY2024, which is 64.48% down from last year.
  • Per Black Diamond Therapeutics' latest filing, its Cash from Financing Activities stood at $25.5 million for FY2024, which was down 64.48% from $71.9 million recorded in FY2023.
  • Black Diamond Therapeutics' 5-year Cash from Financing Activities high stood at $214.9 million for FY2020, and its period low was $177,000 during FY2022.
  • For the 3-year period, Black Diamond Therapeutics' Cash from Financing Activities averaged around $32.6 million, with its median value being $25.5 million (2024).
  • Per our database at Business Quant, Black Diamond Therapeutics' Cash from Financing Activities slumped by 99.66% in 2021 and then spiked by 40,539.55% in 2023.
  • Black Diamond Therapeutics' Cash from Financing Activities (Yearly) stood at $214.9 million in 2020, then slumped by 99.66% to $729,000 in 2021, then tumbled by 75.72% to $177,000 in 2022, then skyrocketed by 40,539.55% to $71.9 million in 2023, then slumped by 64.48% to $25.5 million in 2024.